AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Annexin A5

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P08758

UPID:

ANXA5_HUMAN

Alternative names:

Anchorin CII; Annexin V; Annexin-5; Calphobindin I; Endonexin II; Lipocortin V; Placental anticoagulant protein 4; Placental anticoagulant protein I; Thromboplastin inhibitor; Vascular anticoagulant-alpha

Alternative UPACC:

P08758; D3DNW7; Q6FHB3; Q6FI16; Q8WV69; Q9UDH9

Background:

Annexin A5, known by various names such as Annexin V, Placental anticoagulant protein I, and Vascular anticoagulant-alpha, plays a pivotal role in the blood coagulation cascade. It acts as an indirect inhibitor of the thromboplastin-specific complex, showcasing its anticoagulant properties.

Therapeutic significance:

Given its involvement in recurrent pregnancy loss, a condition marked by spontaneous abortion before 24 weeks of gestation, Annexin A5's study is crucial. Understanding the role of Annexin A5 could open doors to potential therapeutic strategies for managing this pregnancy complication.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.